Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Depreciation and Depletion: 2020-2025

Historic Depreciation and Depletion for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to $81,000.

  • Silence Therapeutics' Depreciation and Depletion fell 5.81% to $81,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $308,000, marking a year-over-year decrease of 31.81%. This contributed to the annual value of $336,000 for FY2024, which is 16.00% down from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' Depreciation and Depletion is $81,000, which was down 0.00% from $81,000 recorded in Q2 2025.
  • Silence Therapeutics' 5-year Depreciation and Depletion high stood at $169,607 for Q1 2021, and its period low was $73,000 during Q1 2025.
  • Its 3-year average for Depreciation and Depletion is $104,139, with a median of $86,000 in 2024.
  • As far as peak fluctuations go, Silence Therapeutics' Depreciation and Depletion tumbled by 63.90% in 2021, and later surged by 91.70% in 2022.
  • Over the past 5 years, Silence Therapeutics' Depreciation and Depletion (MRQ) stood at $86,273 in 2021, then soared by 91.70% to $165,383 in 2022, then decreased by 15.95% to $139,009 in 2023, then tumbled by 45.33% to $76,000 in 2024, then grew by 6.58% to $81,000 in 2025.
  • Its last three reported values are $81,000 in Q3 2025, $81,000 for Q2 2025, and $73,000 during Q1 2025.